A new practical control guide for respiratory disease in cattle can help UK farmers avoid economic losses as a result of the disease, which is estimated to cost the UK cattle industry £80 million annually.
Norbrook® is a true innovator and dedicated to novel research and revolutionary processes and products. The late Lord Ballyedmond, Founder of Norbrook began his career in the pharmaceutical industry in the USA in the 1960s. He started Norbrook in 1969 and it is now one of the largest privately owned pharmaceutical companies in the world.
The company is very active in both medical and veterinary products and Lord Ballyedmond was accredited with developing pharmaceutical science on the continent of Africa and is recognised worldwide for this.
Research and Development is the key to Norbrook’s success with the R&D Department central to the company’s structure. It is responsible for new product development, technical support and meeting regulatory and licensing protocols. Norbrook invests significantly in the research and development of new products.
The company is at the forefront of formulation technology and has developed many new chemical routes for the synthesis of active materials. Norbrook has registered more than 300 product formulations in 120 countries.
The on-going success of the company is conditional on the expertise, knowledge and innovation of the staff employed. Norbrook prides itself on attracting the highest calibre of individual to the company and boasts a multi-national workforce committed to constantly pushing the boundaries and challenging technologies to ensure that Norbrook remains the leading force in pharmaceuticals that it is today.
The Company was also the first in the anthelmintic market to have developed the 'holy grail' - Closamectin Pour On is a painless treatment for internal parasites, external parasites and fluke (both immature and mature) and the sterilisation of eggs.